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Abstract 
Based on the “serotonin hypothesis”, the agents which could increase the 
serotonin transmission in the brain are thought to be effective for the palliation 
of depression. Present study, we investigated the effect of chronic or acute 
treatment with mifepristone, a glucocorticoid receptor antagonist, on the basal 
release of serotonin in the basolateral amygdala (BLA) in rats. The basal 
release of serotonin in the BLA was significantly increased after chronic 
treatment with mifepristone for 14 days. On the other hand, the basal release of 
serotonin in the BLA was not affected by acute treatment with mifepristone. 
These results suggest that mifepristone may have a therapeutic potential for 
depression by novel mechanisms. 
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1. Introduction 
There are many studies on the effect of antidepressants in paradigms designed to 
mimic symptom of human depression (Cryan et al., 2002). Since it is well known that 
hypothalamic-pituitary-adrenal axis is involved in the pathophysiology of depression in 
human (Dinan, 1994; Reus and Miner, 1985), chronic treatment with corticosterone, a 
major glucocorticoid in rodents, has been used as an animal model of depression. For 
example, chronic corticosterone injections increased the immobility time on the forced 
swim test (Gregus et al., 2005; Johnson et al., 2006). In addition, chronic treatment with 
corticosterone has been shown to suppress hippocampal neurogenesis (Mayer et al., 
2006), which might contribute to the hippocampal volume reductions observed in 
depression (Sheline at al., 1996). However, few studies have examined the 
pharmacological mechanisms by which chronic treatment with corticosterone causes the 
depressive-like symptoms. 
The effects of corticosterone are mediated by two types of intracellular receptor 
molecules: glucocorticoidreceptors (GRs) and mineralocorticoidreceptors (MRs). 
Recently, treatment with GR antagonist mifepristone have shown to relieve the 
symptoms of depression in clinical studies (Belanoff et al., 2002; DeBattista et al., 
2006; Flores et al., 2006). In animal models of depression, treatment with mifepristone 
reverses the increased immobility time in the rat forced swim test in a maternal 
separation model (Aisa et al., 2007). Moreover, mifepristone has been reported to 
normalize the reduction in neurogenesis caused by chronic corticosterone injection or 
chronic stress (Mayer et al., 2006; Oomen et al., 2007). These results suggest that 
mifepristone may be effective for the remission from depression. 
It is well known that the central serotonin systems in the brain play a crucial role in 
depression. The mechanism of major effective therapeutic agents, such as tricyclic 
antidepressant (TCA) and selective serotonin reuptake inhibitor (SSRI), involve the 
enhancement of serotonergic neurotransmission in the brain. However, the relationship 
between the central serotonin system and GR has remained unclear. 
Therefore, we investigated the effect of mifepristone on the basal release of 
serotonin in the basolateral amygdala (BLA) in rats. 
 
 
 
2. Materials and methods 
2.1. Animals 
Eight-week-old male Wistar rats were used in the present study. Rats were housed 
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under controlled temperature (24 ± 1C) and light-dark cycle (on 7:00-19:00). Food and 
water were available ad libitum. 
 
2.2. Chronic mifepristone treatment 
Rats were treated with mifepristone, 20 mg/kg, i.p., or saline (control group) twice a 
day (9:00 and 19:00) for 14 days. On the day of the final treatment, surgery for 
implantation of guide cannula was performed. 
 
2.3. Acute mifepristone treatment 
On the next day of the surgery for implantation of guide cannula, rats were treated 
with mifepristone, 20 mg/kg, i.p., or saline (control group) at 9:00. Immediately after 
treatment, basal release of serotonin was measured. 
 
2.4. In vivo microdialysis 
 Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and placed in a 
stereotaxic apparatus. A guide cannula (one site per animal) for microdialysis probe was 
implanted just above the basolateral nucleus of the amygdala (BLA; AP: -2.56 mm, ML: 
5.0 mm, DV: 5.6 mm, from the bregma and skull). The cannula was fixed in place with 
acrylic resin dental cement. 
On the next day of the implantation of a guide cannula, microdialysis probes were 
inserted through the guide cannula into the BLA under brief anesthesia and perfused 
with artificial cerebrospinal fluid (CSF) solution at constant flow rate of 1 l/min (Fig. 
1). A stabilization period of 120 min was established before the onset of experiments. 
The perfused dialysates were collected in the sample pool of an automated sample 
injector and the serotonin contents in the dialysates were measured every 20 min (20 l) 
by HPLC-ECD system connected to the sample injector. 
 
 
Fig. 1  Schematic illustration of the in vivo microdialysis method. 
HPLC-ECD
CSF
（1 μL / min）
guide cannula
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2.5. Statistical analysis 
Data are presented as mean with standard error of the mean (S.E.M.). Two-way 
ANOVA was used to determine the significance of differences between the 
mifepristone-treated group and the saline-treated group. 
 
 
 
3. Results 
3.1. Basal release of serotonin in the BLA in chronically mifepristone-treated rats 
Two-way ANOVA analysis showed that the chronic mifepristone treatment caused a 
slight but significant increase in the basal extracellular level of serotonin in the BLA [p 
< 0.05] (Fig. 2A). The serotonin contents in the dialysates on average for 240 min were 
1.34 0.05 pg in the chronically saline-treated group and 2.68  0.22 pg in the 
chronically mifepristone-treated group, respectively. The total amount of serotonin in 
the dialysates for 240 min were 16.08 3.30 pg in the chronically saline-treated group 
and 32.10  8.50 pg in the chronically mifepristone-treated group, respectively (Fig. 
2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2  Effects of chronic treatment with mifepristone (MPS) on basal release of 
serotonin in the basolateral amygdala. Rats were chronically treated with saline (○) 
or mifepristone 20mg/kg (●) twice a day for 14 days. A: The serotonin contents in 
the dialysates every 20 min. B: The total amount of serotonin in the dialysates for 
240 min. Data are presented as mean with standard error of the mean (S.E.M.) of 
4-5 rats. 
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3.2. Basal release of serotonin in the BLA in acutely mifepristone-treated rats 
The basal extracellular level of serotonin in the BLA was not affected by acute 
treatment with mifepristone [p = 0.67] (Fig. 3). The serotonin contents in the dialysates 
on average for 240 min were 1.63 0.10 pg in the chronically saline-treated group and 
1.97  0.20 pg in the chronically mifepristone-treated group, respectively. The total 
amount of serotonin in the dialysates for 240 min were 19.60 6.00 pg in the 
chronically saline-treated group and 23.59  5.90 pg in the chronically 
mifepristone-treated group, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3  Effects of acute treatment with mifepristone (MPS) on basal release of 
serotonin in the basolateral amygdala. Rats were acutely treated with saline (○) or 
mifepristone20mg/kg (●) just before measurement of serotonin release. A: The 
serotonin contents in the dialysates every 20 min. B: The total amount of serotonin 
in the dialysates for 240 min. Data are presented as mean with standard error of the 
mean (S.E.M.) of 4-5 rats. 
 
 
 
 
4. Discussion 
The present study showed that the basal release of serotonin in the basolateral 
amygdala (BLA) was increased after 14 days treatment with mifepristone in rats. BLA 
receives the serotonergic projections from dorsal raphe nucleus, a largest serotonergic 
nucleus in the brain (Ma et al., 1991). Thus, basal release of serotonin in the BLA has 
been thought to reflect the serotonergic neural activity in the brain. 
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Clinical treatment with mifepristone has been reported to be effective in antagonizing 
the depressive- like behavior of psychotic depression (Belanoff et al., 2002; DeBattista 
et al., 2006; Flores et al., 2006). In animal studies, treatment with mifepristone reverses 
the increased immobility time in the rat forced swim test in a maternal separation model 
(Aisa et al., 2007). In addition, mifepristone normalize the chronic stress- and 
corticosterone-induced reduction of hippocampal neurogenesis (Mayer et al., 2006; 
Oomen et al., 2007), which may contribute to the hippocampal volume reductions 
observed in depression (Henn and Vollmayr, 2004; Jacobs et al., 2000). Thus, present 
result led to the hypothesis that the antagonizing the depressive-like behaviour after 
mifepristone treatment was mediated, at least in part, by increase in the serotonin 
release in the brain. 
Though the mechanisms by which chronic treatment with mifepristone increases the 
basal release of serotonin in the BLA are unclear, quantitative alteration in particular 
functional proteins may be involved. GR is members of the steroid hormone receptor 
superfamily which recognizes specific DNA elements in the regulatory regions of 
genes: glucocorticoid response elements (GREs) and, accordingly, acts as transcription 
factors in the nucleus of the cell to change mRNA and protein synthesis of target genes 
(Fink, 2007). Thus, chronic GR blockade by mifepristone may causes the alteration in 
the expression of particular functional proteins that play an important role in the 
regulation of the basal release of serotonin in the BLA. This hypothesis also explains 
our result that basal release of serotonin in the BLA was not affected by acute treatment 
with mifepristone. Namely, acute treatment with mifepristone may not be enough to 
change the expression of particular functional proteins adequately.  
 Based on the “serotonin hypothesis”, the agents which could increase the serotonin 
transmission in the brain, such as tricyclic antidepressants (TCA) and selective 
serotonin reuptake inhibitors (SSRI), are now commonly used as pharmacotherapies for 
depression (Schatzberg, 2003). Our data demonstrated that chronic treatment 
mifepristone also increase the serotonin transmission in the BLA. Moreover, the 
mechanism by which increases the serotonin transmission may differ from TCA and 
SSRI. Thus, mifepristone may have a therapeutic potential for depression by a novel 
mechanisms. 
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